Absorption and Metabolism of Resveratrol Carboxyesters and Methanesulfonate by Explanted Rat Intestinal Segments

Model prodrugs of resveratrol carrying protecting substituents at the hydroxyls have been synthesised and tested. Resveratrol triacetate and resveratrol-tri-mPEG1900 were formed by linking methyl groups or poly(ethylene glycol) chains, respectively, via carboxyester bonds. Resveratrol trimesylate, a molecule less susceptible to hydrolytic attack, was synthesised as well. This latter compound proved to be stable in vitro, while the carboxyester derivatives were slowly hydrolysed in solutions mimicking the gastric or intestinal environment, and rapidly converted to resveratrol in blood. In ex vivo permeation experiments with explanted intestinal segments, resveratrol and its triacetate derivative appeared in the basolateral compartment essentially as a mixture of Phase II metabolites. When the PEGylated derivative was provided on the apical side, unconjugated resveratrol accounted for about 50% of the compounds in the basolateral-side chamber. The same result was obtained by providing an equivalent physical mixture of resveratrol and PEG polymer, indicating that this behaviour is likely due to an adjuvating effect of PEG rather than to the covalent polymer conjugation. These observations suggest that the ester derivatives are rapidly hydrolysed at the intestinal surface or inside enterocytes, and are then processed as resveratrol. On the other hand, the mesylate was transported from the apical to the basolateral side without modification. It may thus be possible to enhance absorption and hinder metabolism of natural polyphenols by constructing pro-drugs incorporating bonds with appropriate resistance to enzymatic hydrolysis.

[1]  S. Pervaiz,et al.  Resveratrol: its biologic targets and functional activity. , 2009, Antioxidants & redox signaling.

[2]  T. Szekeres,et al.  Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells , 2009, Investigational New Drugs.

[3]  Junmo Kang,et al.  Synthesis of novel trans-stilbene derivatives and evaluation of their potent antioxidant and neuroprotective effects. , 2009, European journal of medicinal chemistry.

[4]  D. Lechuga‐Ballesteros,et al.  Absorption of polyethylene glycol (PEG) polymers: the effect of PEG size on permeability. , 2009, Journal of pharmaceutical sciences.

[5]  S. Passamonti,et al.  Bioavailability of flavonoids: a review of their membrane transport and the function of bilitranslocase in animal and plant organisms. , 2009, Current drug metabolism.

[6]  Ya-jing Shang,et al.  4,4'-Dihydroxy-trans-stilbene, a resveratrol analogue, exhibited enhanced antioxidant activity and cytotoxicity. , 2009, Bioorganic & medicinal chemistry.

[7]  P. Guha,et al.  Improved Antiulcer and Anticancer Properties of a trans-Resveratrol Analog in Mice , 2009, Journal of Pharmacology and Experimental Therapeutics.

[8]  P. Kroon,et al.  Physiologically relevant metabolites of quercetin have no effect on adhesion molecule or chemokine expression in human vascular smooth muscle cells. , 2009, Atherosclerosis.

[9]  A. Mukherjee,et al.  Quercetin and its derivatives: synthesis, pharmacological uses with special emphasis on anti-tumor properties and prodrug with enhanced bio-availability. , 2009, Anti-cancer agents in medicinal chemistry.

[10]  E. A. Rogozin,et al.  The resveratrol analogue 3,5,3′,4′,5′‐pentahydroxy‐trans‐stilbene inhibits cell transformation via MEK , 2008, International journal of cancer.

[11]  P. Jagodziński,et al.  Cytotoxic activity of 3,3',4,4',5,5'-hexahydroxystilbene against breast cancer cells is mediated by induction of p53 and downregulation of mitochondrial superoxide dismutase. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[12]  J. Li,et al.  RV09, a novel resveratrol analogue, inhibits NO and TNF-alpha production by LPS-activated microglia. , 2008, International immunopharmacology.

[13]  Y. Wong,et al.  Effect of a Prodrug of the Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate on the Growth of Androgen-Independent Prostate Cancer In Vivo , 2008, Nutrition and cancer.

[14]  T. Sanderson,et al.  Challenges for research on polyphenols from foods in Alzheimer's disease: bioavailability, metabolism, and cellular and molecular mechanisms. , 2008, Journal of agricultural and food chemistry.

[15]  A. Gosslau,et al.  Trans- and cis-stilbene polyphenols induced rapid perinuclear mitochondrial clustering and p53-independent apoptosis in cancer cells but not normal cells. , 2008, European journal of pharmacology.

[16]  S. Sang,et al.  Bioavailability issues in studying the health effects of plant polyphenolic compounds. , 2008, Molecular nutrition & food research.

[17]  F. Perez-Vizcaino,et al.  Glucuronidated metabolites of the flavonoid quercetin do not auto-oxidise, do not generate free radicals and do not decrease nitric oxide bioavailability. , 2008, Planta medica.

[18]  V. Somoza,et al.  Quantification of free and protein-bound trans-resveratrol metabolites and identification of trans-resveratrol-C/O-conjugated diglucuronides - two novel resveratrol metabolites in human plasma. , 2008, Molecular nutrition & food research.

[19]  G. Lizard,et al.  Inhibitory effects of trans-resveratrol analogs molecules on the proliferation and the cell cycle progression of human colon tumoral cells. , 2008, Molecular nutrition & food research.

[20]  S. Ramos Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. , 2008, Molecular nutrition & food research.

[21]  J. Spencer Food for thought: the role of dietary flavonoids in enhancing human memory, learning and neuro-cognitive performance , 2008, Proceedings of the Nutrition Society.

[22]  B. Aggarwal,et al.  Resveratrol: A multitargeted agent for age-associated chronic diseases , 2008, Cell cycle.

[23]  T. Thalhammer,et al.  Metabolism and disposition of resveratrol in the isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides. , 2008, Journal of pharmaceutical sciences.

[24]  M. Miksits,et al.  Metabolism of resveratrol in breast cancer cell lines: impact of sulfotransferase 1A1 expression on cell growth inhibition. , 2008, Cancer letters.

[25]  J. Hodgson,et al.  Metabolic transformation has a profound effect on anti-inflammatory activity of flavonoids such as quercetin: lack of association between antioxidant and lipoxygenase inhibitory activity. , 2008, Biochemical pharmacology.

[26]  Ying-Jan Wang,et al.  Antitumor activity of 3,5,4′‐trimethoxystilbene in COLO 205 cells and xenografts in SCID mice , 2008, Molecular carcinogenesis.

[27]  Koji Yamada,et al.  Green Tea Polyphenol Epigallocatechin-3-gallate Signaling Pathway through 67-kDa Laminin Receptor* , 2008, Journal of Biological Chemistry.

[28]  S. Sang,et al.  Biotransformation of green tea polyphenols and the biological activities of those metabolites. , 2007, Molecular pharmaceutics.

[29]  M. Torres-Lugo,et al.  Poly(Ethylene Glycol) Hydrogels as Possible Multidrug Resistance Associated Protein (MRP) Inhibitors , 2007, 2007 29th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[30]  S. Mariotto,et al.  Protective effect of epigallocatechin-3-gallate on ischemia/reperfusion-induced injuries in the heart: STAT1 silencing flavonoid , 2007, Genes & Nutrition.

[31]  T. Walle,et al.  Improving metabolic stability of cancer chemoprotective polyphenols , 2007, Expert opinion on drug metabolism & toxicology.

[32]  C. A. Ventura,et al.  In vitro evaluation of quercetin-3-O-acyl esters as topical prodrugs. , 2007, International journal of pharmaceutics.

[33]  Di Chen,et al.  A novel prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate as a potential anticancer agent. , 2007, Cancer research.

[34]  M. Zoratti,et al.  Ester-based precursors to increase the bioavailability of quercetin. , 2007, Journal of medicinal chemistry.

[35]  B. Narayanan,et al.  Chemopreventive agents alters global gene expression pattern: predicting their mode of action and targets. , 2006, Current cancer drug targets.

[36]  Charles Ramassamy,et al.  Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. , 2006, European journal of pharmacology.

[37]  J. K. Kundu,et al.  Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-κB in mouse skin by blocking IκB kinase activity , 2006 .

[38]  Joseph A. Baur,et al.  Therapeutic potential of resveratrol: the in vivo evidence , 2006, Nature Reviews Drug Discovery.

[39]  D. Barron,et al.  Divergent effects of quercetin conjugates on angiogenesis , 2006, British Journal of Nutrition.

[40]  A. Gescher,et al.  Differential modulation of cyclooxygenase-mediated prostaglandin production by the putative cancer chemopreventive flavonoids tricin, apigenin and quercetin , 2006, Cancer Chemotherapy and Pharmacology.

[41]  S. Rapposelli,et al.  Synthesis of a resveratrol analogue with high ceramide-mediated proapoptotic activity on human breast cancer cells. , 2005, Journal of medicinal chemistry.

[42]  L. Chow,et al.  Synthetic peracetate tea polyphenols as potent proteasome inhibitors and apoptosis inducers in human cancer cells. , 2005, Frontiers in bioscience : a journal and virtual library.

[43]  V. Somoza,et al.  Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. , 2005, Molecular nutrition & food research.

[44]  V. Somoza,et al.  Metabolism and bioavailability of trans-resveratrol. , 2005, Molecular nutrition & food research.

[45]  T. Szekeres,et al.  Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. , 2005, Biochemical pharmacology.

[46]  J. Mérillon,et al.  Cellular uptake and efflux of trans-piceid and its aglycone trans-resveratrol on the apical membrane of human intestinal Caco-2 cells. , 2005, Journal of agricultural and food chemistry.

[47]  G. Ecker,et al.  Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. , 2004, Bioorganic & medicinal chemistry.

[48]  G. Williamson,et al.  How should we assess the effects of exposure to dietary polyphenols in vitro? , 2004, The American journal of clinical nutrition.

[49]  J. Thénot,et al.  Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. , 2004, Biochemical and biophysical research communications.

[50]  T. Walle Absorption and metabolism of flavonoids. , 2004, Free radical biology & medicine.

[51]  L. Stivala,et al.  Resveratrol is a Peroxidase-mediated Inactivator of COX-1 but Not COX-2 , 2004, Journal of Biological Chemistry.

[52]  G. Williamson,et al.  Quercetin metabolites downregulate cyclooxygenase-2 transcription in human lymphocytes ex vivo but not in vivo. , 2004, The Journal of nutrition.

[53]  H. Hara,et al.  A Soluble Flavonoid-glycoside, αG-Rutin, Is Absorbed as Glycosides in the Isolated Gastric and Intestinal Mucosa , 2004, Bioscience, biotechnology, and biochemistry.

[54]  G. Williamson,et al.  Absorption of quercetin-3-glucoside and quercetin-4'-glucoside in the rat small intestine: the role of lactase phlorizin hydrolase and the sodium-dependent glucose transporter. , 2003, Biochemical pharmacology.

[55]  T. Walle,et al.  Resveratrol transport and metabolism by human intestinal Caco‐2 cells , 2003, The Journal of pharmacy and pharmacology.

[56]  S. A. Hussain,et al.  Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  G. Williamson,et al.  Conjugation position of quercetin glucuronides and effect on biological activity. , 2000, Free radical biology & medicine.

[58]  G. Williamson,et al.  Intestinal transport of quercetin glycosides in rats involves both deglycosylation and interaction with the hexose transport pathway. , 2000, The Journal of nutrition.

[59]  H. Fischer,et al.  Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo. , 1998, American journal of physiology. Lung cellular and molecular physiology.

[60]  T. Fujita,et al.  Absorption characteristics of chemically modified-insulin derivatives with various fatty acids in the small and large intestine. , 1995, Journal of pharmaceutical sciences.

[61]  G. Sims,et al.  A method for the estimation of polyethylene glycol in plasma protein fractions. , 1980, Analytical biochemistry.

[62]  M. Shakibaei,et al.  Resveratrol addiction: to die or not to die. , 2009, Molecular nutrition & food research.

[63]  Chee-Youb Won,et al.  PEG-modified biopharmaceuticals. , 2009, Expert opinion on drug delivery.

[64]  Martin Werle,et al.  Polymeric and low molecular mass efflux pump inhibitors for oral drug delivery. , 2008, Journal of pharmaceutical sciences.

[65]  S. Sang,et al.  Antioxidative and anti-carcinogenic activities of tea polyphenols , 2008, Archives of Toxicology.

[66]  Sanjay K. Jain,et al.  PEGylation: an approach for drug delivery. A review. , 2008, Critical reviews in therapeutic drug carrier systems.

[67]  J. K. Kundu,et al.  Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. , 2006, Carcinogenesis.

[68]  Gary Williamson,et al.  Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. , 2005, The American journal of clinical nutrition.

[69]  J. Terao,et al.  Effect of quercetin conjugates on vascular permeability and expression of adhesion molecules , 2004, BioFactors.

[70]  P. Caliceti,et al.  Enzyme modification by MPEG with an amino acid or peptide as spacer arms , 1991, Applied Biochemistry and Biotechnology.